Delivery Order SPE2DB22D1202-SPE2DB25FVLC4
Award Date 9/11/25
Potential Completion Date 9/12/25
Potential Value $7.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $46,199.30 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with completion scheduled for August 29, 2025. This is a firm fixed-price, non-set-aside contract executed on August 28, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. REPATHA is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in eligible patient...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-competitive, firm fixed-price delivery order was issued on August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management in patients with cardiovascular...
- The Defense Logistics Agency awarded a delivery order valued at $1,769.15 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract issued on August 5, 2025, with performance at the vendor's Conshohocken, Pennsylvania headquarters. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with established heart...
- The Defense Logistics Agency awarded a delivery order valued at $4,115.11 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed-price delivery order represents a non-competitive procurement and is being fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to lower cholesterol levels and reduce cardiovascular...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors valued at $1,135.11, with completion scheduled for September 9, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, valued at $1,041.42. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,693.21 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor indicated for cholesterol management in eligible...
- The Defense Logistics Agency awarded a delivery order valued at $13,727.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. This non-competitive, firm fixed-price delivery order was awarded on September 9, 2025, with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk in eligible...
- The Defense Logistics Agency awarded a $16,007.47 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with a ceiling value of $1,041.42. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to treat high cholesterol and reduce...